Options Review, Fresh Ideas

Major Options Success:

We try our best to consistently form a steady stream of varied options targets for ourselves and our readers. On Friday we submitted three ideas in our premarket report, and we are pleased to pass along the excellent opportunities to profit that they created during Friday’s session.

Our interests included targets in the MU, SHW, and SPY chains, and as it turned out, each and every target that we put forth produced nice moves on the day. Here are the trading ranges and total possible gains that were recorded.

MU Weekly $91-93 Calls

$91: .47-1.88 (+300%)
$92: .09-.94 (+944%)
$93: .03-.28 (+833%)

SHW 04/16 $246.67-250 Calls
$246.67: 3.50-5.70 (+63%)
$250: 1.90-4.30 (+126%)

SPY Weekly $397-398 Calls
$397: 1.69-4.00 (+137%)
$398: 1.03-2.97 (+188%)

Fresh Options Ideas:
SPY Weekly $401-403 Calls 

EBS 09/17 $95 Calls

Extended Watchlist: 

Bitcoin Options Really Popping

Bitcoin Options Review

At the beginning of last week, we began to pay much closer attention to bitcoin related plays as the digital currency was passing $28K and heading to new highs. We started by tracking the MARA 01/15 $13-15 Calls that morning, and added more targets to the mix this Monday morning in the form of the MARA Weekly $11-12 Calls and the RIOT Weekly $17-19 Calls. In the case of the latter two, they were our first fresh options ideas of the new trading year, so it’s nice to hit on those.

With Bitcoin surging to new all time highs once again, now trading between $34K and $35K we expect to have to come back yet again and report even further gains, but as of yesterday’s close, here were the excellent gains we had witnessed so far: 

RIOT Weekly $17-19 Calls 
$17: .65-2.24 (+245%)
$18: .52-1.67 (+221%)
$19: .35-1.19 (+240%)

MARA Weekly $11-12 Calls
$11: 1.32-3.90 (+195%)
$12: 1.06-3.25 (+207%)

MARA 01/15 $13-15 Calls
: .80-2.72 (+240%)
$14: .62-2.30 (+270%)
$15: .50-1.95 (+290%)

Extended Watchlist: 

CURR News Update & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)

In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below: 


Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com

Fresh Options Ideas:
SPY 01/06 $368-367 Puts

Extended Watchlist: